CMX001 in Post-transplant Patients With BK Virus Viruria

This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus infection. Subjects received blinded study medication for a total of 5 doses in 1 of the following regimens: * 10 mg BCV administered twice weekly (BIW) on Days 0, 3, 7, 10, 14. * 20 mg BCV administered once weekly (QW) on Days 0, 7, and 14 and placebo administered on Days 3 or 10. * Placebo administered BIW on Days 0, 3, 7, 10 ,14. * 40 mg BCV administered QW on Days 0, 7, 14, 21, and 28. * Placebo administered QW on Days 0, 7, 14, 21, and 28.